Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048253 | 0.92 | ADORA2A (0.30) | — | |
| SCHEMBL31617917 | 0.90 | HRH2 (0.31) | ACACBACACASTK17BSTK17A | |
| SCHEMBL31618010 | 0.89 | ADK (0.39) | GFER | |
| SCHEMBL30941089 | 0.88 | HRH2 (0.31) | — | |
| SCHEMBL30940981 | 0.84 | ADORA2A (0.30) | — | |
| SCHEMBL30941110 | 0.82 | ADK (0.42) | — | |
| SCHEMBL31617974 | 0.80 | STK17B (0.37) | ACACBACACASTK17BSTK17A | |
| SCHEMBL25048554 | 0.80 | — | — | |
| SCHEMBL31617962 | 0.79 | METTL3 (0.38) | — | |
| SCHEMBL30941177 | 0.79 | ADK (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | ACACB 3813/4885ACACA 3853/4885GFER 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.